Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Synjardy Contraindications and Alternatives in Autoimmune Diabetes

Regulatory and Guideline Position

  • The American Diabetes Association Standards of Care explicitly state that SGLT2 inhibitors like empagliflozin are approved only for Type 2 diabetes treatment 1
  • European guidelines recommend empagliflozin, canagliflozin, or dapagliflozin specifically in patients with Type 2 diabetes and cardiovascular disease or high cardiovascular risk 2
  • Synjardy is FDA-approved exclusively for Type 2 diabetes mellitus, not Type 1 diabetes or autoimmune diabetes 1

Critical Safety Concerns in Type 1/Autoimmune Diabetes

  • SGLT2 inhibitors significantly increase the risk of diabetic ketoacidosis (DKA) in patients with Type 1 diabetes or insulinopenic diabetes 3
  • The FDA issued a specific warning that SGLT2 inhibitors may lead to euglycemic diabetic ketoacidosis, which is particularly dangerous because it can occur without significant hyperglycemia 4
  • In Type 1 diabetes, concomitant use of insulin and SGLT2 inhibitors substantially increases DKA risk 3

Appropriate Alternatives for Autoimmune Diabetes

  • Insulin remains the cornerstone of treatment for Type 1/autoimmune diabetes 1
  • Pramlintide is the only non-insulin injectable agent FDA-approved for Type 1 diabetes in adults, showing modest A1C reductions of 0.3-0.4% 1

Contraindications and Safety Concerns for Synjardy in Autoimmune Diabetes

Pathophysiology and Treatment Alternatives

  • In patients with autoimmune diabetes, the use of SGLT2 inhibitors like empagliflozin creates a metabolic environment that promotes ketogenesis through enhanced urinary glucose excretion, reducing available substrate, and relative insulin deficiency in the setting of increased glucagon activity 5
  • Basal insulin alone can be initiated at 10 units per day or 0.1–0.2 units/kg/day, depending on the degree of hyperglycemia, as recommended by the American Diabetes Association 5
  • Long-acting basal analogs (U-100 glargine or detemir) are preferred over NPH insulin when adding basal insulin, with a recommended starting dose of mealtime insulin being 4 units, 0.1 units/kg, or 10% of the basal dose 5

Insulin Regimens

  • Many individuals with autoimmune diabetes require mealtime bolus insulin dosing in addition to basal insulin, with rapid-acting analogs preferred due to their prompt onset of action 5